Summary of Key Points Core Viewpoint - A number of companies, including Xiaomi Group and Kuaishou, conducted share buybacks on October 14, 2025, with Xiaomi leading in terms of buyback amount and quantity [1]. Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 4 million shares for a total of 195 million, with a year-to-date total of 10.5954 million shares, representing 0.040% of its total share capital [2]. - Kuaishou-W (01024) repurchased 1.3146 million shares for 98.4067 million, with a year-to-date total of 3.4516 million shares, representing 0.081% of its total share capital [2]. - Shoucheng Holdings (00697) repurchased 16.05 million shares for 36.3578 million, with a year-to-date total of 90.146 million shares, representing 1.237% of its total share capital [2]. Group 2: Other Notable Buybacks - Vitasoy International (00345) repurchased 1.3980 million shares for 11.3964 million, with a year-to-date total of 4.25 million shares, representing 0.405% of its total share capital [2]. - IGG (00799) repurchased 150,000 shares for 6.145 million, with a year-to-date total of 17.809 million shares, representing 1.527% of its total share capital [3]. - China Hongqiao (01378) repurchased 300,000 shares for 7.594 million, with a year-to-date total of 154 million shares, representing 1.650% of its total share capital [2].

Group 1 - The company, Guichuang Tongqiao (02190), announced a share buyback plan on October 14, 2025, involving an expenditure of HKD 1.2073 million to repurchase 50,000 shares [1] - The repurchase price per share ranges from HKD 23.94 to HKD 25 [1]

Group 1 - The company, Zhichuang Tongqiao (02190), announced a share buyback plan on October 14, 2025, involving an expenditure of HKD 1.2073 million to repurchase 50,000 shares [1] - The repurchase price per share is set between HKD 23.94 and HKD 25 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年10月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Insights - The Hong Kong stock market has seen a significant increase in the number of unprofitable biotech companies listing under Chapter 18A, with 11 companies listed this year compared to 4 last year, indicating a growing trend in this sector [1][2] - Many of these companies have performed exceptionally well post-listing, with seven companies seeing stock price increases of over 100%, highlighting strong market interest and investor confidence [1][2] - The ability of these companies to transition from unprofitable to profitable status, marked by the removal of the "B" designation, is crucial for their long-term success and market valuation [1][3] Expansion of the 18A Sector - As of October 13, 2023, the 18A sector has welcomed 11 new listings this year, with significant fundraising achievements, including a record $268 million from Jinfang Pharmaceutical-B [2] - Companies like Yinnuo Pharmaceutical-B and Paige Biopharma-B are focusing on high-demand areas such as GLP-1 drug development, showcasing the sector's innovative and diverse directions [2] - The 18A sector continues to attract interest, with 24 companies currently in the pipeline for listing, indicating a robust future for this segment [2] Financial Performance and Market Dynamics - Since the introduction of Chapter 18A in 2018, 78 companies have successfully listed, raising approximately HKD 131.64 billion and achieving a total market capitalization of nearly HKD 1.5 trillion [3] - The influx of overseas capital into the Hong Kong market has enhanced liquidity, with daily trading volumes exceeding HKD 200 billion, positively impacting company valuations [3] - The successful removal of the "B" designation is a key milestone for these companies, reflecting their commercial viability and market acceptance [3][4] Commercialization and Profitability - Companies like CloudTop and Guichuang Tongqiao have successfully transitioned to profitability, with CloudTop reporting a 461% revenue increase in 2024, marking a significant achievement in their business journey [4][5] - The success of biotech firms hinges on their ability to navigate clinical trials and effectively market their approved drugs, as failure to do so can hinder profitability and lead to financial instability [5][6] - Investors are increasingly focusing on the commercialization capabilities of these companies, shifting from speculative investments to those based on tangible performance [6][7] Future Outlook and Strategic Developments - The valuation logic for the 18A sector is expected to evolve from pipeline expectations to the validation of commercialization capabilities, supported by advancements in technology platforms [7] - The introduction of the "Tech Company Fast Track" by the Hong Kong Stock Exchange aims to streamline the listing process for biotech firms, potentially leading to more efficient market entries [7] - The ongoing collaboration between Hong Kong and mainland regulatory bodies is anticipated to foster a conducive environment for biotech innovation, enhancing the sector's role in global markets [7]

格隆汇10月13日丨归创通桥(02190.HK)公告，10月13日耗资120.8万港元回购5万股，每股回购价24.42- 24.82港元。 ...

Group 1 - The company, Zhichuang Tongqiao (02190), announced a share buyback plan, intending to repurchase 50,000 shares at a cost of HKD 1.2079 million [1]

Group 1 - The company, Guichuang Tongqiao (02190), announced a share buyback plan [1] - The total amount allocated for the buyback is HKD 1.2079 million [1] - The company plans to repurchase 50,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出 ...

Group 1 - The company, Guichuang Tongqiao (02190), announced a share buyback on October 10, 2025, spending HKD 1.2315 million to repurchase 50,000 shares [1] - The repurchase price per share ranged from HKD 24.42 to HKD 24.82 [1]